Fzata’s capturing the “holy grail” of oral biologics with our transformational Bioengineered Probiotic Yeast Medicines (BioPYM) modality. With $17M in non-dilutive NIH funding, Fzata has developed a pipeline of drug candidates for gastrointestinal-related disorders. BioPYM platform uses live yeast as a ‘factory’ to make recombinant therapeuticbiologics in the gut. Advantages over traditional biologics include: simple yeast manufacturing, no anti-drug antibody response, no toxicity, no refrigeration and no needles. BioPYM FZ002 first-in-human phase 1 clinical trial. for C. diff infection will be in 2023. Next is FZ006 for ulcerative colitis and Crohn's disease.

Health Care

Fzata, Inc.

Org chart

Teams

Similar companies